Breast Neoplasms |
NCT02627248: Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery |
|
|
| Recruiting | 4 | 200 | RoW | Huaier Granule, Epirubicin, Docetaxel, Cyclophosphamide | Shandong University | Breast Cancer | 10/25 | 10/25 | | |
NCT02615457: Huaier Granule in Treating Women With Triple Negative Breast Cancer |
|
|
| Recruiting | 4 | 300 | RoW | Huaier Granule | Shandong University | Triple Negative Breast Cancer | 10/25 | | | |
PROCAPP, NCT01626781: A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer |
|
|
| No Longer Available | 3 | | Europe | Mapisal, Urea hand-foot cream | AIO-Studien-gGmbH | the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine | | | | |
| Active, not recruiting | 3 | 257 | Europe | trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery | Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis | Breast Cancer | 08/17 | 09/25 | | |
|
PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer |
|
|
| Recruiting | 3 | 320 | RoW | NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel | Shi Yanxia | Breast Cancer Model, Effects of Chemotherapy, Breast Cancer | 03/18 | 03/23 | | |
NCT01185132: Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy |
|
|
| Recruiting | 3 | 660 | US | accelerated partial breast irradiation - 3D-conformal planning, APBI, EBRT, accelerated partial breast irradiation - IMRT planning | Rocky Mountain Cancer Centers | Breast Cancer | 07/18 | 07/28 | | |
NCT02595138: Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer |
|
|
| Active, not recruiting | 3 | 430 | RoW | Zoledronic acid | Chinese Academy of Medical Sciences, Beijing Municipal Science & Technology Commission | Triple Negative Breast Cancer | 10/18 | 12/23 | | |
NCT02958033: Shandong Cancer Hospital Affiliated to Shandong University |
|
|
| Recruiting | 3 | 100 | RoW | Whole Breast irradiation Plus simultaneous tumor bed Boost | Shandong Cancer Hospital and Institute | Early-stage Breast Cancer, Breast Conserving Surgery | 11/19 | 11/24 | | |
| Recruiting | 3 | 280 | Europe | stereotactic body radiation therapy, Systemic treatment | Gustave Roussy, Cancer Campus, Grand Paris | Breast Cancer | 06/25 | 02/26 | | |
| Active, not recruiting | 3 | 878 | RoW | taxane plus carboplatin, Taxane | Yonsei University | Breast Cancer | 06/25 | 06/25 | | |
NCT03137368: A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) |
|
|
| Enrolling by invitation | 3 | 300 | RoW | Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test, Tamoxifen | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Pfizer | CYP2D6 Polymorphism | 10/23 | 10/23 | | |
NCT02097459: Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer |
|
|
| Recruiting | 3 | 600 | RoW | Anastrozole, Arimidex, Tamoxifen, Toremifene, Fareston, Shu Rui | Peking Union Medical College Hospital | Breast Cancer | 03/24 | | | |
NCT02132390: Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea |
|
|
| Not yet recruiting | 3 | 300 | RoW | Goserelin, Zoladex, Toremifene | Peking Union Medical College Hospital | Breast Cancer, Chemotherapy Induced Amenorrhea, Ovarian Function Suppression | 05/24 | | | |
TACT2, NCT00301925: Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery |
|
|
| Active, not recruiting | 3 | 4400 | Europe | pegfilgrastim, capecitabine, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate, adjuvant therapy | Institute of Cancer Research, United Kingdom | Breast Cancer | 09/24 | 09/24 | | |
NACVCAC, NCT03011060: Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer |
|
|
| Recruiting | 3 | 1588 | RoW | Neo-adjuvant Chemotherapy, Preoperative Chemotherapy, Primary Chemotherapy, Induction Chemotherapy, Capecitabine, Xeloda | The First Hospital of Jilin University, First Hospital of China Medical University, The Second Affiliated Hospital of Harbin Medical University, Qingdao University, First Affiliated Hospital Xi'an Jiaotong University, Baotou Cancer Hospital | Breast Neoplasm Female | 12/24 | 02/25 | | |
NCT02448576: PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy |
|
|
| Not yet recruiting | 3 | 326 | RoW | prophylactic cranial irradiation | wang shusen | Breast Cancer, Brain Metastasis | 08/25 | 08/25 | | |
NCT00194337: Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer |
|
|
| | 2/3 | 400 | US | breast imaging study, comparison of screening methods, magnetic resonance imaging, positron emission tomography, radiomammography, ultrasound imaging, fludeoxyglucose F 18 | Abramson Cancer Center of the University of Pennsylvania, National Cancer Institute (NCI) | Breast Cancer | 07/12 | | | |
SHPD002, NCT02221999: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2/3 | 250 | RoW | Paclitaxel, Taxol, Cisplatin, Gonadotropin-releasing hormone agonist, Letrozole | RenJi Hospital | Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer | 01/19 | 01/29 | | |
plasmaMATCH, NCT03182634: The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices () Trial |
|
|
| Recruiting | 2a | 1150 | Europe | Fulvestrant, Neratinib, AZD5363, Olaparib, AZD6738 | Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust | Advanced Breast Cancer | 11/22 | 11/23 | | |
|
NCT01216124: Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients |
|
|
| Available | 2 | | US | docetaxel oxaliplatin | Fudan University, Chinese Anti-Cancer Association | Triple Negative Local Advanced Breast Cancer | | | | |
|
APBI, NCT01185145: Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy |
|
|
| Active, not recruiting | 2 | 291 | US | Breast Brachytherapy with Mammosite RTS, Mammosite, Breast Brachytherapy, Accelerated Partial Breast Irradiation, APBI, Intensity Modulated Radiotherapy, IMRT, EBRT | Rocky Mountain Cancer Centers, Charles Leonard, MD | Breast Cancer | 08/14 | 08/24 | | |
NCT01740271: A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients |
|
|
| Recruiting | 2 | 48 | Canada | Epirubicin | AHS Cancer Control Alberta | Breast Neoplasms | 06/15 | 06/25 | | |
NCT01560416: Fulvestrant With or Without Ganetespib in HR+ Breast Cancer |
|
|
| Active, not recruiting | 2 | 50 | US | Fulvestrant, Faslodex, Ganetespib, STA9090 | Dana-Farber Cancer Institute | Breast Cancer | 06/16 | 12/24 | | |
| Active, not recruiting | 2 | 90 | Europe | accelerated partial breast irradiation | National Institute of Oncology, Hungary | Breast Cancer, Radiation Toxicity, Side Effects | 03/19 | 03/24 | | |
NCT00496288: Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer |
|
|
| Recruiting | 2 | 240 | RoW | Prophylactic radiation to the contralateral breast | Assaf-Harofeh Medical Center, Rambam Health Care Campus, Tel-Aviv Sourasky Medical Center, Sheba Medical Center, Soroka University Medical Center, Western Galilee Hospital-Nahariya, Rabin Medical Center | Breast Cancer | 03/23 | | | |
NCT02927912: Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction |
|
|
| Recruiting | 2 | 176 | Canada, US | Electron Beam Therapy, photon beam radiation therapy, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Reconstructive Surgery, Reconstruction | Ohio State University Comprehensive Cancer Center | Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer | 12/24 | 12/24 | | |
NCT02491697: Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer |
|
|
| Active, not recruiting | 2 | 400 | RoW | DC-CIK Immunotherapy, DC-CIK, Capecitabine Monotherapy, Capecitabine | The First People's Hospital of Changzhou | Breast Cancer | 08/30 | 08/33 | | |
NCT01251874: Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer |
|
|
| Active, not recruiting | 1 | 44 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorothymidine F-18, 18F-FLT, 3'-Deoxy-3'-(18F) Fluorothymidine, 3'-deoxy-3'-[18F]fluorothymidine, ALOVUDINE F-18, Fluorothymidine F 18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888 | National Cancer Institute (NCI) | Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma | 04/17 | 08/25 | | |
|
|
|
NCT02762110: Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer |
|
|
| Recruiting | 1 | 30 | US | N-(4-(6,7-dimethoxy-3,-4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-[18F]- fluoroethoxy)-5-methylbenzamide (18F-3c) ([18F]ISO-1), Positron emission tomography (PET/CT) imaging | Abramson Cancer Center of the University of Pennsylvania | Breast Cancer | 10/19 | | | |
NCT01322750: Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma |
|
|
| Recruiting | N/A | 3125 | US | | Walter Reed Army Medical Center, Bureau of Navy Medicine (BUMED) | Breast Abnormality | 01/13 | 01/23 | | |
NCT01130259: An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer |
|
|
| No Longer Available | N/A | | US | iniparib, BSI-201 | Sanofi | Breast Cancer | | | | |
PRIMUNEO, NCT01513408: Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy |
|
|
| Active, not recruiting | N/A | 500 | Europe | immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio | Centre Georges Francois Leclerc | Breast Cancer | 10/15 | 10/25 | | |
NCT02755987: Expanded Access to ANG1005 for Individual Patients |
|
|
| No Longer Available | N/A | | US | ANG1005 | Angiochem Inc | Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis | | | | |
NCT01120561: A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer |
|
|
| No Longer Available | N/A | | US | trastuzumab-MCC-DM1 | Genentech, Inc. | Metastatic Breast Cancer | | | | |
|
ECHO, NCT03062072: Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients |
|
|
| Recruiting | N/A | 300 | RoW | Chemotherapy, cytotoxic chemotherapeutic agents | National Cancer Center, Korea, SMG-SNU Boramae Medical Center | Cancer, Colon Cancer, Breast Cancer, Malignant Lymphoma | 12/17 | 12/22 | | |
| Recruiting | N/A | 2000 | RoW | | Samsung Medical Center | Breast Cancer | 02/18 | 04/23 | | |
NCT03067935: Individual Patient Expanded Access-Glembatumumab Vedotin |
|
|
| No Longer Available | N/A | | NA | glembatumumab vedotin | Celldex Therapeutics | Metastatic gpNMB Expressing Triple Negative Breast Cancer | | | | |
NCT02142868: Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate |
|
|
| No Longer Available | N/A | | Canada, US | Palbociclib, Ibrance, Letrozole, Femara | Pfizer | Advanced Breast Cancer (Female) | | | | |
NCT02559544: [18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 50 | US | [18F]Fluoroestradiol (FES) PET/CT Imaging | Abramson Cancer Center of the University of Pennsylvania | Recurrent ER+ Breast Cancer, Metastatic ER+ Breast Cancer | 05/19 | 05/19 | | |
NCT02389699: Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ |
|
|
| Active, not recruiting | N/A | 74 | RoW | Intraoperative Radiotherapy, Whole breast radiation | Liao Ning | Breast Neoplasms | 06/19 | 06/24 | | |
NCT02389673: Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer |
|
|
| Recruiting | N/A | 222 | RoW | Intraoperative Radiotherapy | Liao Ning | Breast Neoplasms | 06/19 | 06/26 | | |
NCT02110160: 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 75 | US | FDG PET/CT, Fluorodeoxyglucose F 18 Injection (FDG) | Abramson Cancer Center of the University of Pennsylvania | Bone Dominant Metastatic ER+ Breast Cancer | 09/19 | | | |
NCT02389686: Intra-operative Radiotherapy For Breast Cancer Women After NSM |
|
|
| Recruiting | N/A | 110 | RoW | INTRABEAM (Carl Zeiss, Oberkochen, Germany) | Liao Ning | Breast Neoplasms | 10/19 | 10/24 | | |
| Recruiting | N/A | 750 | Europe | molecular alteration | Institut Paoli-Calmettes | Breast Cancer | 12/19 | 12/29 | | |
NCT02774473: [18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy |
|
|
| Recruiting | N/A | 20 | US | [18F]FLT PET/CT, Paclitaxel | Abramson Cancer Center of the University of Pennsylvania | Breast Neoplasms | 02/20 | | | |
| Recruiting | N/A | 420 | US | Permanent Breast Seed Implant (PBSI), Breast Microseed Treatment | Concure Oncology-Breast Microseed Inc. | Breast Neoplasms | 07/21 | 07/26 | | |
| Recruiting | N/A | 200 | US | Visica 2 Treatment System, Visica Breast Therapy | Sanarus Technologies, Inc. | Breast Cancer | 12/21 | 06/23 | | |
NCT02861209: Collaborative Network to Take Responsibility for Oral Anticancer Therapy |
|
|
| Recruiting | N/A | 228 | Europe | Implementation of a care pathway | KU Leuven | Breast Cancer, ALL, Lung Cancer, Melanoma, Colorectal Cancer, Prostate Cancer | 11/22 | 11/22 | | |
| Recruiting | N/A | 30 | Europe | | Hospital Universitari Vall d'Hebron Research Institute | Pregnancy, Breast Cancer | 12/22 | | | |
NCT02464774: Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer |
|
|
| Not yet recruiting | N/A | 464 | RoW | Breast-Conserving Therapy, Mastectomy, Adjuvant Chemotherapy, Radiation Therapy | Xiaoming Xie | Breast Cancer | 12/22 | | | |
| Completed | N/A | 314 | Europe | quality of life assessment | Institut Cancerologie de l'Ouest | Breast Cancer, Melanoma | 02/23 | 02/23 | | |
NCT00690196: Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms |
|
|
| Active, not recruiting | N/A | 90 | US | Tai Chi Chih, TCC, Cognitive Behavioral Therapy, CBT | Jonsson Comprehensive Cancer Center, National Center for Research Resources (NCRR) | Sleep Disorders, Sleep Initiation and Maintenance Disorders, Dyssomnias, Mental Disorders, Nervous System Diseases | 07/24 | 07/25 | | |
NCT02884284: Prospective and Retrospective Breast Cancer Database |
|
|
| Recruiting | N/A | 10000 | Europe | clinical biological database collection | Institut Claudius Regaud | Breast Cancer | 01/25 | 12/25 | | |
NCT02506361: Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer |
|
|
| Recruiting | N/A | 800 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 05/25 | 10/25 | | |
| Recruiting | N/A | 40 | Europe | supervision of physical activity, distance supervised physical activity | Centre Hospitalier Universitaire, Amiens | Breast Cancer | 11/25 | 11/25 | | |
NCT02271828: Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy |
|
|
| Recruiting | N/A | 1644 | Europe | Sentinel lymph node procedure | Maastricht University Medical Center, Borstkanker Onderzoek Groep, Dutch Cancer Society, Maastricht University | Breast Neoplasms | 04/27 | 04/27 | | |
NCT02869607: Institut Paoli Calmettes Breast Cancer Database |
|
|
| Recruiting | N/A | 45000 | Europe | Data collection | Institut Paoli-Calmettes | Breast Cancer Diagnosis | 01/30 | 12/30 | | |
| Recruiting | N/A | 16000 | Europe | Data collection | Institut Paoli-Calmettes | Lymphoma | 01/30 | 12/30 | | |
NCT01445275: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 |
|
|
| Withdrawn | N/A | 2605 | US | Evaluation of Cancer Risk Factors, cancer risk factors evaluation, Medical Chart Review, Chart Review, Study of Socioeconomic and Demographic Variables | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 01/16 | | | |